{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:20Z","timestamp":1792511900684,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,10,31]],"date-time":"2013-10-31T00:00:00Z","timestamp":1383177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00417-013-2495-0","type":"journal-article","created":{"date-parts":[[2013,10,30]],"date-time":"2013-10-30T02:24:48Z","timestamp":1383099888000},"page":"331-337","source":"Crossref","is-referenced-by-count":93,"title":["Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes"],"prefix":"10.1007","volume":"252","author":[{"given":"Elad","family":"Moisseiev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Waisbourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Ben-Artsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliya","family":"Levinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adiel","family":"Barak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tad","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Csaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Loewenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina S.","family":"Barequet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,31]]},"reference":[{"issue":"9827","key":"2495_CR1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","volume":"379","author":"LS Lim","year":"2012","unstructured":"Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379(9827):1728\u20131738","journal-title":"Lancet"},{"key":"2495_CR2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ajo.2010.11.017","volume":"151","author":"RJ Brechner","year":"2011","unstructured":"Brechner RJ, Rosenfeld PJ, Babish JD, Caplan S (2011) Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 151:887\u2013895","journal-title":"Am J Ophthalmol"},{"key":"2495_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2011.10.001","volume":"87","author":"MW Stewart","year":"2012","unstructured":"Stewart MW (2012) The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc 87:77\u201388","journal-title":"Mayo Clin Proc"},{"key":"2495_CR4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"RPA Manzano","year":"2007","unstructured":"Manzano RPA, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Ch\u00e9vez-Barrios P (2007) Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 91:804\u2013807","journal-title":"Br J Ophthalmol"},{"key":"2495_CR5","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00006982-200604000-00001","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383\u2013390","journal-title":"Retina"},{"key":"2495_CR6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"F Bock","year":"2007","unstructured":"Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545\u20132552","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ophtha.2008.02.013","volume":"115","author":"SW Kim","year":"2008","unstructured":"Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI (2008) The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 115:33\u201338","journal-title":"Ophthalmology"},{"key":"2495_CR8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","volume":"27","author":"HS Uy","year":"2008","unstructured":"Uy HS, Chan PS, Ang RE (2008) Topical bevacizumab and ocular surface neovascularization in patients with Stevens\u2013Johnson syndrome. Cornea 27:70\u201373","journal-title":"Cornea"},{"key":"2495_CR9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","volume":"27","author":"MH Dastjerdi","year":"2009","unstructured":"Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R, Pavan-Langston D, Dana R (2009) Topical bevacizumab in the treatment of corneal neovascularization. Arch Ophthalmol 27:381\u2013389","journal-title":"Arch Ophthalmol"},{"key":"2495_CR10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","volume":"125","author":"JJ DeStafeno","year":"2007","unstructured":"DeStafeno JJ, Kim T (2007) Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 125:834\u2013836","journal-title":"Arch Ophthalmol"},{"key":"2495_CR11","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","volume":"50","author":"H Nomoto","year":"2009","unstructured":"Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T (2009) Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50:4807\u20134813","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR12","first-page":"322","volume":"86","author":"E Yoeruek","year":"2008","unstructured":"Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P, T\u00fcbingen Bevacizumab Study Group (2008) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Arch Ophthalmol 86:322\u20138","journal-title":"Arch Ophthalmol"},{"key":"2495_CR13","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","volume":"52","author":"MH Dastjerdi","year":"2001","unstructured":"Dastjerdi MH, Sadrai Z, Saban DR, Zhang Q, Dana R (2001) Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 52:8718\u20138723","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jop.2009.0022","volume":"26","author":"MJ Kim","year":"2010","unstructured":"Kim MJ, Han ES, Kim JW, Kim TW (2010) Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit. J Ocul Pharmacol Ther 26:49\u201353","journal-title":"J Ocul Pharmacol Ther"},{"key":"2495_CR15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1755-3768.2009.01842.x","volume":"90","author":"CH Meyer","year":"2012","unstructured":"Meyer CH, Krohne TU, Holz FG (2012) Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans. Acta Ophthalmol 90:68\u201370","journal-title":"Acta Ophthalmol"},{"key":"2495_CR16","first-page":"1007","volume":"44","author":"HM Xu","year":"2008","unstructured":"Xu HM, Zhou YX, Shi MG (2008) Exploration of three-dimensional biometric measurement of emmetropic adult eye-ball by using magnetic resonance imaging technology. Zhonghua Yan Ke Za Zhi 44:1007\u20131010","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"2495_CR17","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","volume":"87","author":"MR Prausnitz","year":"1998","unstructured":"Prausnitz MR, Noonan JS (1998) Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. J Pharm Sci 87:1479\u20131488","journal-title":"J Pharm Sci"},{"key":"2495_CR18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/bjo.2005.066225","volume":"89","author":"HM Brereton","year":"2005","unstructured":"Brereton HM, Taylor SD, Farrall A, Hocking D, Thiel MA, Tea M, Coster DJ, Williams KA (2005) Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol 89:1205\u20131209","journal-title":"Br J Ophthalmol"},{"key":"2495_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-07","volume":"9","author":"A Galor","year":"2010","unstructured":"Galor A, Yoo SH (2010) Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 9:1\u20133","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"2495_CR20","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","volume":"50","author":"TI Kim","year":"2009","unstructured":"Kim TI, Chung JL, Hong JP, Min K, Seo KY, Kim EK (2009) Bevacizumab application delays epithelial healing in rabbit cornea. Invest Ophthalmol Vis Sci 50:4653\u20134659","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"J Gaudreault","year":"2005","unstructured":"Gaudreault J, Fei D, Ruzit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of ranibizumab after a single intravitreal administration. Invest Ophthalmol Vis Sci 46:726\u2013733","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Y Koenig","year":"2009","unstructured":"Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C (2009) Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 247:1375\u20131382","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2495_CR23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","volume":"50","author":"F Bock","year":"2009","unstructured":"Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schl\u00f6tzer-Schrehardt U, Cursiefen C (2009) Safety profile of topical VEGF neutralization at the cornea. Invest Ophthalmol Vis Sci 50:2095\u20132102","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335\u2013345","journal-title":"Angiogenesis"},{"key":"2495_CR25","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.iae.0000233327.68433.02","volume":"26","author":"PM Beer","year":"2006","unstructured":"Beer PM, Wong SJ, Hammad AM, Falk NS, O\u2019Malley MR, Khan S (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871\u2013876","journal-title":"Retina"},{"key":"2495_CR26","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.ophtha.2008.04.023","volume":"115","author":"Q Zhu","year":"2008","unstructured":"Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S, T\u00fcbingen Bevacizumab Study Group (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-a in patients with choroidal neovascularization. Ophthalmology 115:1750\u20131755","journal-title":"Ophthalmology"},{"key":"2495_CR27","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1097\/IAE.0b013e318217373c","volume":"31","author":"CH Meyer","year":"2011","unstructured":"Meyer CH, Krohne TU, Holz FG (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5\u00a0mg versus 3.0\u00a0mg of bevacizumab in humans. Retina 31:1877\u20131884","journal-title":"Retina"},{"key":"2495_CR28","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1167\/iovs.10-6862","volume":"52","author":"JB Christofordis","year":"2011","unstructured":"Christofordis JB, Carlton MM, Knopp MV, Hinkle GH (2011) PET\/CT imaging of I-124-radiolabeled bevacizumab and ranibizumab after intravitreal injection in a rabbit model. Invest Ophthalmol Vis Sci 52:5899\u20135903","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"2495_CR30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/OPTH.S19555","volume":"5","author":"CI Sinapis","year":"2011","unstructured":"Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, Theocharis SE, Baltatzis S, Patsouris E, Perrea D (2011) Pharmacokinetics of intravitreal bevacizumab (Avastin) in rabbits. Clin Ophthalmol 5:697\u2013704","journal-title":"Clin Ophthalmol"},{"key":"2495_CR31","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1167\/iovs.07-0871","volume":"49","author":"H Kim","year":"2008","unstructured":"Kim H, Fariss RN, Zhang C, Robinson SB, Thill M, Csaky KG (2008) Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci 49:2025\u20132029","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2495_CR32","first-page":"2803","volume":"15","author":"H Kim","year":"2009","unstructured":"Kim H, Robinson SB, Csaky KG (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 15:2803\u20132812","journal-title":"Mol Vis"},{"key":"2495_CR33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715\u2013725","journal-title":"Nat Rev Immunol"},{"key":"2495_CR34","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","volume":"25","author":"HS Chin","year":"2005","unstructured":"Chin HS, Park TS, Moon YS, Oh JH (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25:556\u2013560","journal-title":"Retina"},{"key":"2495_CR35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","volume":"110","author":"PM Beer","year":"2003","unstructured":"Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB, Miller M (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681\u2013686","journal-title":"Ophthalmology"},{"key":"2495_CR36","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajo.2007.02.048","volume":"144","author":"A Yanyali","year":"2007","unstructured":"Yanyali A, Aytug B, Horozoglu F, Nohutcu AF (2007) Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144:124\u2013126","journal-title":"Am J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-013-2495-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-013-2495-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-013-2495-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:29:51Z","timestamp":1688585391000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-013-2495-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,31]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2495"],"URL":"https:\/\/doi.org\/10.1007\/s00417-013-2495-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,31]]}}}